U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy

Not Applicable

Completed

• Conditions: Surgery; Renal Stone; Analgesia
• Interventions: Procedure: Intra-venous Morphine; Procedure: Continous Quadratum Lumborum Block III; Procedure: Single dose Quadratum Lumborum Block III

• Registration Number: NCT04800302
• Lead Sponsor: Nazmy Edward Seif

Brief Summary

Percutaneous nephrolithotomy (PCNL) is considered to be the first choice and a more conservative procedure than open stone surgery. Not only postoperative pain related to dilatation of the renal capsule and parenchymal tract, but also patient's discomfort \& nephrostomy tube-related stress are reported to delay recovery time and increase the complication rates. This study is designed to provide postoperative analgesia by using ultrasound-guided continuous Quadratus Lumborum Block (QLB) III in patients undergoing PCNL and to assess pain scores \& side effects with less opioids consumption.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-03-12
• Study First Submitted QC: 2021-03-15
• Study First Posted: 2021-03-16
• Study Start: 2021-06-10
• Primary Completion: 2022-06-28
• Study Completion: 2022-06-28
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-21
• Last Update Posted: 2022-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• ASA I-II.
• Scheduled for percutaneous nephrolithotomy (PCNL).

Exclusion Criteria

• Patient refusal.
• Coagulation disorders.
• Skin lesions or infection at site of needle insertion.
• Known allergy to local anesthetics or opioids.
• Patients suffering from neurological or mental disease.
• Procedure turned into open stone surgery.
• Failure of identification by U/S.
• Urinary tract malignancies.
• Opioid consumption 48 hours before the operation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Morphine group	Intra-venous Morphine	IV Morphine
Continuous QLB group	Single dose Quadratum Lumborum Block III	U/S-guided continous QLB III
Continuous QLB group	Continous Quadratum Lumborum Block III	U/S-guided continous QLB III
Single dose QLB group	Single dose Quadratum Lumborum Block III	U/S-guided single dose QLB III
Single dose QLB group	Intra-venous Morphine	U/S-guided single dose QLB III
Continuous QLB group	Intra-venous Morphine	U/S-guided continous QLB III

Primary Outcome Measures

Name	Time	Method
Morphine consumption.	24 hours	Total dose of Morphine (measured in mg) given intra-venously to the patient post-operatively.

Trial Locations

Locations (1)

Cairo University Hospitals; 🇪🇬 Cairo, Egypt